Madeleine Johnson

Global organizations are calling for an increase in diagnostic tests — particularly point-of-care molecular assays — to meet the challenge of a new outbreak.

Bio-Rad is expecting a decline in revenues for the full year due to a slower pace of recovery among customers of its core businesses.

The San Diego-based in vitro diagnostics company plans to reduce its real estate footprint by selling facilities in California and New Jersey.

The firm announced its four-year plan on Monday during an analyst day event held at the New York Stock Exchange.

New systems to directly detect nucleic acids from patient samples are on the horizon, but still fall short of gold standard amplification-based techniques and likely face a difficult regulatory path.

The dashboard is intended to provide information about flu A levels based on molecular wastewater testing and is also incorporated into the agency's H5N1 monitoring strategies.

The Alphabet health technology company found bird flu in Texas sewage, but CDC is not currently planning to monitor this pathogen.

The firm said it expects to reinstate guidance and reschedule its Investor Day at some point this year as new CEO Brian Blaser continues to assess the business.

The firm expects sales in its clinical diagnostics business to offset declines in life sciences related in part to lower instrument sales.

In its diagnostics business, declining sales of its NeuMoDx systems were offset by growth in QiaStat-Dx and QuantiFeron tuberculosis testing.